Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$73.30 USD

73.30
7,101,316

+1.66 (2.32%)

Updated Jul 17, 2024 04:00 PM ET

After-Market: $73.34 +0.04 (0.05%) 6:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $85.41 in the latest trading session, marking a -1% move from the prior day.

Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ONEY

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Is iShares Select Dividend ETF (DVY) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DVY

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $87.19, marking a +0.06% move from the previous day.

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Is Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for LVHD

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $85.50 in the latest trading session, marking a +0.13% move from the prior day.

Gilead's (GILD) Application for Trodelvy Gets EMA Validation

by Zacks Equity Research

Gilead Sciences (GILD) gets EMA validation for its application for breast cancer drug Trodelvy in the European Union.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $85.26, marking a +0.82% move from the previous day.

Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More

by Zacks Equity Research

Updates from Gilead Sciences (GILD) and ProQR (PRQR) are the key highlights from the biotech sector during the past week.

Andrew Rocco headshot

Biotech: 3 Profitable Bios Worth Owning

by Andrew Rocco

The biotechnology space can be a difficult area to generate profits. Drugs take years to develop and often fail FDA approval. Today we will look at three top biotech stocks that are very profitable and have attractive future prospects.

Gilead (GILD) To Get Full Rights for Jounce's Immunotherapy

by Zacks Equity Research

Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from Jounce Therapeutics.

Zacks Industry Outlook Highlights Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals

by Zacks Equity Research

Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals are part of the Zacks Screen of the Week article.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $85.01, marking a +0.31% move from the previous day.

4 Top Biotech Stocks Worth Adding to Your Portfolio in 2023

by Zacks Equity Research

New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, GSK, IMCR and SNDX well amid the volatility.

Gilead (GILD) Gets FDA Nod for Twice-Yearly HIV Treatment

by Zacks Equity Research

Gilead'ls (GILD) HIV franchise gets a boost with FDA's approval of twice-yearly HIV treatment Sunlenca for the treatment of HIV-1 infection in heavily treatment-experienced adults with multi-drug resistance.

Andrew Rocco headshot

Biotech is Set for a Blockbuster 2023: Here's Why

by Andrew Rocco

The biotech sector has been outperforming the major U.S. indices for the past few months. Can the strength continue?

Roche (RHHBY) Actemra Gets FDA Nod for Adults With COVID-19

by Zacks Equity Research

Roche (RHHBY) obtains FDA approval for Actemra (tocilizumab) intravenous (IV) for the treatment of COVID-19 in hospitalized adult patients. The drug was earlier granted an EUA.

Ekta Bagri headshot

Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More

by Ekta Bagri

Pipeline updates from Madrigal (MDGL) and Entrada (TRDA) are the key highlights from the biotech sector during the past week.

Merck (MRK), Seagen Keytruda-Padcev sBLAs Get FDA Priority Tag

by Zacks Equity Research

Merck (MRK) and Seagen's (SGEN) sBLAs seek approval of Padcev plus Keytruda for locally advanced or metastatic urothelial cancer in patients who are not eligible for cisplatin-containing chemotherapy.

Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?

by Zacks Equity Research

Here is how Gilead Sciences (GILD) and HealthEquity (HQY) have performed compared to their sector so far this year.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $84.77 in the latest trading session, marking a -1.91% move from the prior day.

Entrada (TRDA) Down on Regulatory Update for DMD Candidate

by Zacks Equity Research

Entrada (TRDA) plunges on clinical hold notice from the FDA regarding its Investigational New Drug Application (IND) for Duchenne muscular dystrophy (DMD) candidate.

bluebird's (BLUE) SCD Studies Clinical Hold Lifted by the FDA

by Zacks Equity Research

bluebird (BLUE) announces that the partial clinical hold on studies evaluating lovo-cel for sickle cell disease (SCD) for patients under the age of 18 has now been lifted.